A. M. Pappas & Associates
19
21M
18
0.05
8
- Areas of investment
Summary
The venture was found in North America in United States. The leading representative office of defined Corporate Investor is situated in the Durham.
We also calculated 4 valuable employees in our database.
Among the most popular fund investment industries, there are Therapeutics, Pharmaceutical. Among the most popular portfolio startups of the fund, we may highlight CeNeRx BioPharma, Dynogen Pharmaceuticals, BrainCells. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has no exact preference in some founders of portfolio startups.
The typical case for the fund is to invest in rounds with 5-6 participants. Despite the A. M. Pappas & Associates, startups are often financed by Wakefield Group, Sears Capital Management, Perseus-Soros Biopharmaceutical Fund. The meaningful sponsors for the fund in investment in the same round are Montreux Equity Partners, Domain Associates, Canaan Partners. In the next rounds fund is usually obtained by Pappas Ventures, Wellcome Trust, Varian.
The average startup value when the investment from A. M. Pappas & Associates is 10-50 millions dollars. Considering the real fund results, this Corporate Investor is 3 percentage points less often commits exit comparing to other organizations. The high activity for fund was in 2002. The fund is generally included in less than 2 deals every year. Deals in the range of 10 - 50 millions dollars are the general things for fund. The top amount of exits for fund were in 2013. Opposing the other organizations, this A. M. Pappas & Associates works on 21 percentage points more the average amount of lead investments.
Investments analytics
Analytics
- Total investments
- 19
- Lead investments
- 0
- Exits
- 8
- Follow on index
- 0.05
- Investments by industry
- Biotechnology (15)
- Health Care (12)
- Medical (10)
- Health Diagnostics (5)
- Biopharma (4) Show 9 more
- Investments by region
-
- United States (19)
- Peak activity year
- 2002
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 20
- Avg. valuation at time of investment
- 113M
- Group Appearance index
- 1.00
- Avg. company exit year
- 9
- Avg. multiplicator
- 6.86
- Strategy success index
- 0.30
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Cognetix | 31 Jul 2001 | Biotechnology, Medical, Pharmaceutical | Early Stage Venture | 17M | Salt Lake City, Utah, United States |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.